GFM1 and mitochondrial disease: Our laboratory previously demonstrated that the combination of polydatin and nicotinamide holds promise as a therapeutic option for pathogenic GFM1 variant-related mitochondrial diseases by activating the mitochondrial unfolded protein response (mtUPR) [24].